Overcoming Drug Resistance in Difficult-to-Treat Rheumatoid Arthritis

Key Summary:

• Drug resistance affects up to half of methotrexate users and one-third of biologic-treated individuals.
• Acquired resistance stems from multidrug efflux pumps, anti-drug antibodies, and alternative cytokine loops.
• Emerging approaches like cellular therapy and targeted nanocarriers offer paths to overcome refractory disease

RHEUMATOID arthritis management encounters major hurdles when complex drug resistance mechanisms undermine frontline and targeted pharmacotherapies. Despite substantial advances in synthetic and biologic therapies, approximately 6% to 21% of individuals develop difficult-to-treat  rheumatoid arthritis, experiencing persistent inflammation and functional decline despite trying multiple targeted agents. Methotrexate resistance occurs in roughly 30% to 50% of clinical cases, while resistance to biologic agents reaches 30% to 40%. Unraveling these pharmacologic and molecular roadblocks is crucial for clinicians striving to restore therapeutic control.

Transporter and Epigenetic Drivers of Drug Resistance

Frontline treatment failure with methotrexate frequently involves cellular transport disruptions. Impaired influx via organic anion transporter 3 and reduced folate carriers limits intracellular drug accumulation. Simultaneously, ATP-binding cassette efflux pumps, notably P-glycoprotein and breast cancer resistance protein, actively remove the antimetabolite from synovial cells and lymphocytes. Metabolic shifts, including accelerated glycolysis driven by the hypoxia-inducible factor pathway, provide excess energy to sustain this active drug efflux. Epigenetic modifications, such as aberrant DNA methylation and altered non-coding RNA profiles, lock fibroblast-like synoviocytes into an aggressive, inflammatory state that evades apoptosis.

Immunogenicity and Cytokine Bypass Pathways

For biologic disease-modifying antirheumatic drugs, the formation of anti-drug antibodies represents a primary cause of secondary therapeutic failure. These antibodies neutralize active binding sites or trigger rapid clearance by macrophages. Chimeric constructs pose higher immunogenic risks, whereas fully human antibodies and fusion proteins demonstrate variable susceptibility influenced by patient human leukocyte antigen haplotypes. Concomitant immunosuppressants, such as methotrexate, help mitigate antibody generation by expanding regulatory B cell populations and boosting adenosine release. Beyond immunogenicity, persistent joint destruction occurs when inflammatory signaling shifts toward alternate cytokine pathways, including interleukin-6, interleukin-17, and granulocyte-macrophage colony-stimulating factor cascades that circumvent targeted receptor blockade.

Innovative Approaches to Refractory Joint Disease

Addressing refractory disease requires comprehensive evaluation of true pharmacologic failure, treatment adherence, and misdiagnoses. Emerging strategies focus on precision interventions, including chimeric antigen receptor T-cell therapies that eradicate autoreactive B cells and engineered nanocarriers designed to suppress synovial efflux pumps. Dual cytokine inhibition, low-dose interleukin-2 therapy to expand regulatory T cells, and implantable vagus nerve neurostimulation devices also demonstrate clinical potential. Leveraging multi-omics profiling will ultimately enable personalized treatment selection, helping rheumatologists overcome multi-agent resistance and achieve lasting clinical remission.

 

 

 

This is only for your information, kindly take the advice of your doctor for food, medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  

https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    

https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

We hope Indian ingenuity will help make cellular therapy for cancer affordable, says Dr Siddhartha Mukherjee

Cancer physician, scientist and author of Pulitzer-winning, The Emperor of All Maladies, Dr. Mukerjee,, is setting up a cellular therapy facility in Bengaluru in the hope of developing drugs. On the sidelines of an event, he tells why personalised medicine and diet are the next frontier for cancer treatment.

At your lab in Columbia University , you and your team of scientists are researching ' living rugs' made from our own cells for cancer treatment. How does this cellular therapy work and what is its potential?
In some forms of leukemia, we could not achieve good results because drugs couldn't distinguish between cancerous and healthy cells. When we attacked the cancer cell, we also attacked the normal one. The idea we patented in my lab is to use gene editing to change the normal cells. For much of the history of cancer, we've focused on cancer cells. Here, we're inverting the logic and saying let's make the normal cells resistant to the therapy with help of gene editing, thereby making the cancer uniquely sensitive to therapy. This uses the human body, the host of cancer, as the element of change. We couldn't change the normal cells earlier because we didn't have the tools, Gene editing provides us with those tools. And all of a sudden, cancer becomes exposed.

How did you think of approaching the problems like this?
The idea occured to me while I was onvacation to Mexico city. I was making drawing with my daughter. One way to make a drawing is to make a black silhouette on white paper. And you can also make a white silhouette in black paper. And I was doing these drawings and began to realise that in cancer we've been using the cancer silhouette against the normal host as the paradign for all treatments. But what if we used the  host as the background and then attack cancer cells? We patented the idea and showed that it can eradicate this untreatable form of leukemia--- acute myeloid leukemia--- in animals and we're rapidly progressing to human studies.

What more can cells tell us about cancer?
A 2nd approach to cancer, we've taken is to ask the question whether other kinds of cells in the body, apart from T-cells, can be used for immunotherapy. One particular type of cell which has never been harnessed before is myeloid, which is a white blood cell and our body's first line of defence against infection. These can penetrate solid tumours, such as ovarian cancer and breast cancer, where Y-cells have not been very successful. A final and 3rd area that we've worked on extensively is personalising cancer medicine. The great irony of cancer is that while it grows so rapidly inside the body, it is difficult to cultivate outside in a lab. But work done by Dutch molecular geneticist, Hans Clevers in the past 10 years whose how to grow cancer cells in a dish. The cells multiply to make a 3-dimensional cluster called an organoid. So, now we take an individual's cancer cells, grow then in a dish and find out what cancer it is and what drugs does it respond to. This allows us to individuate cancer therapy. We're just about to publish a paper to show how you can find completely new cancer drugs and therapies. We're slowly moving away from the protocol-driven therapies which are sort of one-size-fits-all.

The food-is-medicine approach is a grey area in modern science. But your lab is researching the impact of diet on cancers. What have you found so far?
 
We. as a community, have neglected diet for long. Diet is part of the micro-environment of cancer cells, which sustains them. We- and many more labs- have started studying the role of diet in a highly systematic and scientific manner. Certain chemotherapies lead to a rise in blood sugar and hence insulin, which controls sugar. It's a side-effect. And insulin allows cancer cells to become resistant to a particular form of chemotherapy. By reducing the amount of insulin, for instance, through manipulation of the diet ( consuming lots of protein, little fat and no carbs) you can make cancers sensitive to chemotherapy. It's important to note that it's a combination of diet and drugs. The diet on its own won\t help. Human trials for this study are about to start. We\re testing it for lymphoma and endometrial cancers.

You've set up a cellular therapy facility in Bengaluru. Why did you choose India?
 
This is a collaboration with Kiran Majumdar Shaw. We hopefully will be able to deliver T-cell therapy and other cell therapies which have previously been unavailable in India. While the facility has already started we're not producing cells yet because you require incredible infrastructure to make these living drugs. Why India? Because we hope it will bring down the cost of these therapies. In India, the combination of engineering and scientific ingenuity has been able to bring the costs down in IT and tech industries. We are hoping to use the same innovative capacity of local scientists and doctors to be able to reduce the cost five to ten fold and make cellular therapies accessible to more people.


this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   
https://gscrochetdesigns.blogspot.com. one can see my crochet creations 
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement